Details of the Drug

General Information of Drug (ID: DMG324Y)

Drug Name
AMG 145
Indication
Disease Entry ICD 11 Status REF
Hypercholesterolaemia 5C80.0 Phase 3 [1]
Cross-matching ID
TTD ID
D0OW2S

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9) TTBRG7E PCSK9_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypercholesterolaemia
ICD Disease Classification 5C80.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01854918) Open Label Study of Long Term Evaluation Against LDL-C Trial-2. U.S. National Institutes of Health.
2 PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40.